Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

Stock Information for Lucid Diagnostics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lucid Diagnostics Inc.

PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025
NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD
Lucid Diagnostics Announces Closing of Public Offering of Common Stock

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.